Laurie Toich, Assistant Editor

Significant opportunities exist for the development of new drugs for relapsing remitting multiple sclerosis.

If one-quarter of HIV-negative patients took PrEP, a significant amount of new HIV infections could be prevented.

Huntington’s disease may be linked to a toxic build-up of urea in the brain.

Trastuzumab is an oncology biologic drug that is indicated for multiple types of cancer.

Hydroxyurea is indicated to decrease the prevalence of painful crises and the need for transfusions in pediatric patients aged 2 years and older with sickle cell anemia with moderate-to-severe painful crises.

The FDA recently approved nivolumab (Opdivo) for the treatment of patients with melanoma whose disease has spread to the lymph nodes or those with metastatic disease who have undergone resection, according to a press release.

Officials with the FDA recently approved cabozantinib (Cabometyx) for the first-line treatment of patients with advanced renal cell carcinoma (RCC), according to a press release.

Officials with the FDA granted accelerated approval to bosutinib (Bosulif) for the treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).

A combination of long-acting beta agonists and inhaled corticosteroids may not increase mortality risk for patients with asthma.

Treatment with hydroxyurea increased hemoglobin F levels for patients with sickle cell anemia.

The FDA issued new draft guidances to expedite the approval of novel targeted drugs.

Nivolumab (Opdivo) showed better tolerability than ipilimumab (Yervoy) in patients with metastatic melanoma.

Officials with the FDA have approved pertuzumab (Perjeta, Roche) in combination with trastuzumab and chemotherapy as an adjuvant therapy for patients with early-stage human epidermal growth factor receptor 2 positive (HER2+) breast cancer who are at high risk of experiencing recurrence.

Unmarried patients were 45% more likely to die from heart disease than married patients.

Pertuzumab (Perjeta) plus trastuzumab and chemotherapy improved invasive disease-free survival in patients with HER2+ breast cancer.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Cabozantinib (Cabometyx) was previously granted priority review as a therapy for advanced renal cell carcinoma.

Bosutinib (Bosulif) was approved by the FDA to treat patients with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia.

Trastuzumab (Herceptin) is indicated to treat HER2+ breast and gastric cancers.

Patients treated with chemotherapy biweekly were 17% less likely to experience breast cancer recurrence over 10 years.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Luxturna (voretigene neparvovec-rzyl) is indicated to treat confirmed biallelic RPE65 mutation-associated retinal dystrophy.

The average profit from cancer drugs administered by 340B hospitals was nearly 50% in 2015.

CAR T cell therapy resulted in a high response rate among previously-treated patients with multiple myeloma.

Polatuzumab vedotin plus bendamustine and rituximab increased complete response rates to 40% among patients with diffuse large B-cell lymphoma.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Homeopathic products may be subject to risk-based policies under proposed FDA rule.